IBA 与 Framatome 成立合资公司 Ekalia，将在欧洲和北美工业化生产 Astatine-211（首座法国南特厂预计2028年投产）

Louvain-la-Neuve, Belgium, and Paris, France, 16 October 2026, 8:00 a.m.
– IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and radiopharmaceutical production solutions, and Framatome, an international leader in nuclear energy committed, among other activities, to the industrial development of products and services for human health through its Framatome Healthcare brand, today announce the establishment of a joint venture (JV) named Ekalia, with its dedicated logo:
The Ekalia JV is dedicated to deploying an international network of industrial-scale Astatine-211 (²¹¹At) production sites close to customers, making this promising radioisotope available for future targeted cancer therapies. Jointly owned by the two partners, the new company combines IBA’s cutting-edge cyclotron and isotope production technologies with Framatome’s nuclear industrial expertise. Together, the two companies intend to establish a network of production sites across Europe and North America.
Addressing a major challenge in nuclear medicine
Astatine-211 is considered a promising alpha-emitting radioisotope for precision nuclear medicine
1
. With its favorable half-life, this alpha emitter can deliver highly concentrated radiation over a very short distance, potentially destroying cancer cells, while minimizing exposure to surrounding healthy tissue
2
. However, translating this clinical potential into patient care requires reliable, large-scale production infrastructure capable of serving as many patients as possible.
Ekalia aims to address this challenge by progressively deploying an international network of industrial Astatine-211 production sites. The first production site is planned in Nantes, France, and is expected to become operational in 2028. Ekalia’s strategy also includes plans for a second pilot site in the United States, followed by the deployment of additional production sites across Europe and the United States to support customers using Astatine-211.
Combining innovation with industrial excellence
Framatome and IBA have already achieved pioneering advances in the field of theranostics
3
. IBA recently
launched the Cyclone
®
iKure cyclotron
, dedicated to the production of Astatine-211. Through
PanTera
, IBA has also established itself as a leading player in advancing the production of Actinium-225, another key isotope for targeted alpha therapy.
For its part, Framatome’s technology, through its ISOGEN joint venture with Kinetrics, enabled the first large-scale commercial production of the radioisotope Lutetium-177 in a power reactor in Canada in June 2022, ensuring reliable, large-scale access to this essential medical radioisotope for targeted prostate cancer therapy.
Through this alliance, IBA and Framatome are setting new benchmarks in the field of theranostics, reinforcing their commitment to driving innovation and improving global access to life-saving treatments.
A partnership supporting new cancer therapies
Catherine Vandenborre, Chief Corporate and Ventures Officer at IBA
, commented: “
This joint venture reflects our determination to actively help remove the barriers limiting patient access to innovations in nuclear medicine. By combining our technological leadership with Framatome’s industrial expertise, we are creating the conditions required to make Astatine-211 available at scale and support the development of new cancer therapies.
”
François Gauché, Vice President of Framatome Healthcare,
added: “
Future targeted therapies require reliable, scalable and resilient supply chains. By joining forces with IBA, we are beginning the development of an international industrial production network for Astatine-211 capable of sustainably supporting the growth of this market and the development of innovative treatments for the benefit of patients.
”
***Ends***
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-laNeuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB)
More information can be found at:
www.iba-worldwide.com
CONTACTS
Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com
Nathalie van Ypersele
Head of Communication and Sustainability
Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com
Framatome Media Contact
Contact presse :
press@framatomemedia.com
www.framatome.com
1
Lindegren et al. EJNMMI Radioph. and Chem. (2026)
11
, 15
doi:10.1186/s41181-026-00428-0
2
Albertsson P et al; Frontiers in Med (2023),
9
, 1076210:
doi:10.3389/fmed.2022.1076210
.
3
The combination of a radioactive imaging isotope to locate a lesion and a therapeutic isotope to destroy the identified target.